214 related articles for article (PubMed ID: 37987124)
21. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.
Han J; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Chang E; Kim SH
Medicine (Baltimore); 2023 Sep; 102(39):e35094. PubMed ID: 37773854
[TBL] [Abstract][Full Text] [Related]
23. [Effect of hypophosphatemia on the prognosis of critically ill patients].
Jiang J; Bao J; Yang R; Zhang H; Wang Y; Zhang H
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Aug; 34(8):858-862. PubMed ID: 36177931
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
Ann Intern Med; 2023 Dec; 176(12):1577-1585. PubMed ID: 37956428
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
27. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.
Garneau WM; Jones-Beatty K; Ufua MO; Mostafa HH; Klein SL; Burd I; Gebo KA
JAMA Netw Open; 2022 Nov; 5(11):e2244141. PubMed ID: 36445705
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
[TBL] [Abstract][Full Text] [Related]
30. [Clinical characteristics and prognostic factors of adult patients with acute respiratory failure due to influenza infection].
Duan J; Yang Y; Hou S; Xing X; Sun M; Liu Y; Xing L
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1304-1309. PubMed ID: 33463487
[TBL] [Abstract][Full Text] [Related]
31. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
medRxiv; 2022 Oct; ():. PubMed ID: 36324801
[TBL] [Abstract][Full Text] [Related]
32. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.
Congdon S; Narrowe Z; Yone N; Gunn J; Deng Y; Nori P; Cowman K; Islam M; Rikin S; Starrels J
Sci Rep; 2023 Nov; 13(1):19688. PubMed ID: 37951998
[TBL] [Abstract][Full Text] [Related]
33. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.
Edelstein GE; Boucau J; Uddin R; Marino C; Liew MY; Barry M; Choudhary MC; Gilbert RF; Reynolds Z; Li Y; Tien D; Sagar S; Vyas TD; Kawano Y; Sparks JA; Hammond SP; Wallace Z; Vyas JM; Barczak AK; Lemieux JE; Li JZ; Siedner MJ
medRxiv; 2023 Jun; ():. PubMed ID: 37425934
[TBL] [Abstract][Full Text] [Related]
36. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
Ranard BL; Chow CC; Megjhani M; Asgari S; Park S; Vodovotz Y
J Med Virol; 2023 Jun; 95(6):e28854. PubMed ID: 37287404
[TBL] [Abstract][Full Text] [Related]
37. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
38. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
39. [Correlation between malnutrition and delirium in elderly patients with severe pneumonia undergoing invasive mechanical ventilation].
Miao L; Shen X; Du Z; Liao J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Oct; 35(10):1053-1057. PubMed ID: 37873709
[TBL] [Abstract][Full Text] [Related]
40. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
